CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase Ib Trial of Vemurafenib Plus Copanlisib to Enhance Radioiodine Avidity in Radioiodine-Refractory Thyroid Cancers

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04462471
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:21.037420+00:00
Published At: 2025-02-28T00:00:00+00:00
Record Updated At: 2025-09-08
Results Posted At: 2025-02-28
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Thyroid Carcinoma", "Thyroid Cancer", "Thyroid Cancer, Follicular", "Thyroid Cancer (Follicular Cell)", "Thyroid Cancer, Papillary", "BRAF V600E Mutation Positive"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-09-08"
protocolSection.identificationModule.nctId: "NCT04462471"
protocolSection.identificationModule.officialTitle: "A Phase Ib Trial of Vemurafenib Plus Copanlisib to Enhance Radioiodine Avidity in Radioiodine-Refractory Thyroid Cancers"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2025-02-28"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.